Full history for every metric is available with a Kvantra account
Advanced Oncotherapy plc (AVO.L)
Key financial summary
Financials in GBP| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | £m | -24 | - | |||||
| Net profit | £m | -10 | -14 | -21 | -21 | -30 | -35 | - |
| EPS reported | £ | -0.09 | - | |||||
| Operating cashflow per share | £ | -0.08 | -0.08 | |||||
| Capex per share | £ | 0.02 | 0.02 | |||||
| FCF per share | £ | -0.10 | -0.10 | |||||
| Free cash flow | £m | -39 | 0 | |||||
| Net debt | £m | 49 | 0 | |||||
| Book value equity | £m | 61 | - | |||||
| Book value per share | £ | 0.16 | - | |||||
| Number of shares | m | 382.48 | 494.89 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.02 | 0.11 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.04 | -0.24 | |||||
| EV/EBITDA LTM | x | -2.36 | -2.74 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -2425.2% | -526.62% | |||||
| FCF Yield | % | -2674.0% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | -57.44% | -66.81% | |||||
| ROIC | % | -17.46% | -17.46% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.73 | - | |||||
| Net Debt/EBITDA | x | -2.29 | -2.29 | |||||
| EBIT/Net interest | x | -4.12 | -4.12 | |||||
| Net debt/market cap | % | 3377.9% | 0.00% | |||||
| Net debt/Equity | x | 0.80 | - | |||||
| Gross debt/equity | x | 0.87 | - | |||||
Company overview
Advanced Oncotherapy plc, alongside its affiliated entities, specializes in the development, production, and distribution of sophisticated proton-based radiotherapy systems aimed at treating cancer. A key initiative for the company involves advancing its Linac Image Guided Hadron Technology (LIGHT) system, an innovative proton therapy solution specifically engineered for oncology applications. Furthermore, the firm oversees the management of properties within the healthcare sector. Its operational reach extends across the United Kingdom, Switzerland, and the United States. Established in 1994, the company was initially incorporated as CareCapital Group plc before adopting its current name, Advanced Oncotherapy PLC, in September 2012. Its principal offices are located in London, UK.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Advanced Oncotherapy plc (AVO.L)
Advanced Oncotherapy plc, alongside its affiliated entities, specializes in the development, production, and distribution of sophisticated proton-based radiotherapy systems aimed at treating cancer. A key initiative for the company involves advancing its Linac Image Guided Hadron Technology (LIGHT) system, an innovative proton therapy solution specifically engineered for oncology applications. Furthermore, the firm oversees the management of properties within the healthcare sector. Its operational reach extends across the United Kingdom, Switzerland, and the United States. Established in 1994, the company was initially incorporated as CareCapital Group plc before adopting its current name, Advanced Oncotherapy PLC, in September 2012. Its principal offices are located in London, UK.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free